Sat Kartar Life Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹212 Cr
- P/E
- 13.34
- ROE
- 26.74%
- PEG
- 0.17
- Price to sales
- 1.10
- Debt to equity
- 0.04
- 52W high / low
- ₹205 / ₹116
- EBITDA margin
- 12.76%
- Net profit margin
- 8.22%
- Promoter holding
- 63.62%
- Sales (last year)
- ₹194 Cr
Incorporated in June 2012, Sat Kartar Shopping Limited is an Ayurveda healthcare company that delivers natural wellness solutions for therapeutic and lifestyle products.[1]
Guidance scorecard · Q2 FY27 call
What Sat Kartar Life Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ2 FY27 call
20–40%- Sat Kartar Life targets a revenue growth of 30% to 35% year-on-year, subject to business conditions and execution.
- For FY27, revenue guidance is around INR300 crores, slightly lowered from earlier estimates due to earlier hospital business integration.
- FY28 revenue target remains at INR500 crores, backed by hospital business ramp-up and product sales growth.
- Hospital vertical expected to contribute INR150-200 crores by FY28, with 300 beds targeted by FY27 and 1,000 beds by FY28.
- New hospitals planned mainly in North India during FY27; South Indian expansion, including collaboration with Jeena Sikho, expected in FY28.
- US market entry expected to start generating revenue from November 2026, with future international expansion contemplated in UAE and potentially Europe.
2 more points from Sat Kartar Life Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ2 FY27 call
Up 2%+See what Sat Kartar Life Ltd said on margins — free account, 30 seconds.
CapexQ2 FY27 call
Planned- Top capital allocation priority for FY27 and FY28 is hospitals.
- No plans to enhance or invest in the factory.
- Focus on maintaining marketing spend at around 40% of revenue.
- Developing in-house AI capabilities to reduce costs, a major ongoing project.
- Expanding hospital network with 10 to 30-bed units for faster breakeven.
- Plans to add around 300 beds by FY27 and 1,000 beds by FY28, including collaboration with Jeena Sikho in South India from FY28.
2 more points from Sat Kartar Life Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ2 FY27 call
See what Sat Kartar Life Ltd said on fundraising — free account, 30 seconds.
Order bookQ2 FY27 call
Ask what Sat Kartar Life Ltd said on the order book →
Full Q2 FY27 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Sat Kartar Life Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Sat Kartar Life Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Sat Kartar Life Ltd
Shareholding breakup across reporting periods.
| Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|
| Promoters + | 63.34% | 63.43% | 63.62% | 63.49% |
| FIIs + | 6.31% | 0.44% | 0.13% | 0.77% |
| DIIs + | 3.70% | 3.10% | 2.26% | 1.86% |
| Public + | 26.65% | 33.03% | 34.00% | 33.44% |
| Others + | 0.00% | 0.00% | 0.00% | 0.43% |
| No. of Shareholders | 425 | 717 | 846 | 1,032 |
Pros & Cons
Sat Kartar Life Ltd
Key positives and risks surfaced from the company insights section.
- Mar 2025 Mar 2026 Average Ticket Size INR 3,000 Concall Transcript - 03 Nov 2025 “Earlier, our average ticket size was in the range of 3,000” Page 15 · Source 3,250 Concall Transcript - 09 May 2026 “200 crores divided by 3250 is the number of orders” Page 7 · Source Daily Unique Leads leads/day 20,000 Presentation - 17 May 2025 “20,000 Daily Unique Leads” Page 7 · Source 25,000 Presentation - 06 May 2026 “25,000 Daily Unique Leads” Page 6 · Source Hospital Bed Capacity beds 0 Concall Transcript - 03 Nov 2025 “First Phase of 30 beds by first quarter of 2027” Page 11 · Source 30 Presentation - 06 May 2026 “Bed Capacity- 30 Beds” Page 11 · Source Number of SKUs SKUs 60 Presentation - 17 May 2025 “60+ SKUs” Page 7 · Source 160 Presentation - 06 May 2026 “160+ SKUs” Page 6 · Source Pincodes Served pincodes 11,600 Presentation - 17 May 2025 “We serve to more than 11,600 Pincodes across India” Page 11 · Source 12,000 Presentation - 06 May 2026 “We serve to more than 12,000+ Pincodes across India” Page 14 · Source Repeat Customer % % 25 Presentation - 17 May 2025 “25% Repeat Customers drive predictable, low-cost revenue.” Page 9 · Source 25 Presentation - 06 May 2026 “25% Repeat Customers drive predictable, low-cost revenue.” Page 16 · Source South India Revenue Share % 30.00 Presentation - 17 May 2025 “South India : 30%” Page 11 · Source 57.60 Presentation - 06 May 2026 “South India : 57.6%” Page 14 · Source Team Strength employees 1,000 Presentation - 17 May 2025 “1000+ Team Strength” Page 7 · Source 2,500 Presentation - 06 May 2026 “2500+ Team Strength” Page 6 · Source
- Mar 2025 Mar 2026 Average Ticket Size INR 3,000 Concall Transcript - 03 Nov 2025 “Earlier, our average ticket size was in the range of 3,000” Page 15 · Source 3,250 Concall Transcript - 09 May 2026 “200 crores divided by 3250 is the number of orders” Page 7 · Source Daily Unique Leads leads/day 20,000 Presentation - 17 May 2025 “20,000 Daily Unique Leads” Page 7 · Source 25,000 Presentation - 06 May 2026 “25,000 Daily Unique Leads” Page 6 · Source Hospital Bed Capacity beds 0 Concall Transcript - 03 Nov 2025 “First Phase of 30 beds by first quarter of 2027” Page 11 · Source 30 Presentation - 06 May 2026 “Bed Capacity- 30 Beds” Page 11 · Source Number of SKUs SKUs 60 Presentation - 17 May 2025 “60+ SKUs” Page 7 · Source 160 Presentation - 06 May 2026 “160+ SKUs” Page 6 · Source Pincodes Served pincodes 11,600 Presentation - 17 May 2025 “We serve to more than 11,600 Pincodes across India” Page 11 · Source 12,000 Presentation - 06 May 2026 “We serve to more than 12,000+ Pincodes across India” Page 14 · Source Repeat Customer % % 25 Presentation - 17 May 2025 “25% Repeat Customers drive predictable, low-cost revenue.” Page 9 · Source 25 Presentation - 06 May 2026 “25% Repeat Customers drive predictable, low-cost revenue.” Page 16 · Source South India Revenue Share % 30.00 Presentation - 17 May 2025 “South India : 30%” Page 11 · Source 57.60 Presentation - 06 May 2026 “South India : 57.6%” Page 14 · Source Team Strength employees 1,000 Presentation - 17 May 2025 “1000+ Team Strength” Page 7 · Source 2,500 Presentation - 06 May 2026 “2500+ Team Strength” Page 6 · Source
Financials of Sat Kartar Life Ltd
Quarterly Results
Quarter-by-quarter operating performance
Financials of Sat Kartar Life Ltd
Profit & Loss
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| Sales + | 52 | 83 | 128 | 163 | 194 | 212 |
| Expenses + | 49 | 78 | 118 | 149 | 169 | 183 |
| Operating Profit | 3 | 5 | 10 | 14 | 25 | 29 |
| OPM % | 5% | 6% | 8% | 9% | 13% | 14% |
| Other Income + | -0 | 0 | 0 | 1 | 2 | 1 |
| Interest | 0 | 0 | 1 | 1 | 1 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 3 | 4 |
| Profit before tax | 2 | 3 | 9 | 13 | 23 | 25 |
| Tax % | 7% | 27% | 27% | 25% | 26% | |
| Net Profit + | 1 | 3 | 6 | 10 | 17 | 19 |
| EPS in Rs | 1.24 | 2.24 | 5.63 | 6.24 | 10.96 | 12.02 |
| Dividend Payout % | -0% | -0% | 3% | 11% | 6% |
Financials of Sat Kartar Life Ltd
Balance Sheet
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.70 | 0.70 | 3 | 16 | 16 | 16 |
| Reserves | 0 | 3 | 7 | 36 | 52 | 72 |
| Borrowings + | 8 | 4 | 2 | 6 | 2 | 2 |
| Other Liabilities + | 3 | 8 | 11 | 7 | 14 | 13 |
| Total Liabilities | 12 | 15 | 22 | 65 | 84 | 103 |
| Fixed Assets + | 5 | 4 | 8 | 6 | 11 | 12 |
| CWIP | -0 | -0 | -0 | 0 | 1 | -0 |
| Investments | 0 | 0 | 0 | 0 | 1 | 3 |
| Other Assets + | 8 | 11 | 14 | 58 | 71 | 88 |
| Total Assets | 12 | 15 | 22 | 65 | 84 | 103 |
Financials of Sat Kartar Life Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | 7 | -5 | 0 | ||
| Cash from Investing Activity + | -3 | -0 | -9 | ||
| Cash from Financing Activity + | -3 | 34 | -1 | ||
| Net Cash Flow | 2 | 28 | -9 | ||
| Free Cash Flow | 7 | -10 | -7 | ||
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 98% | -13% | 26% |
Financials of Sat Kartar Life Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 1 | 0 | 7 | 13 | 26 |
| Inventory Days | 31 | 25 | 23 | 185 | 258 |
| Days Payable | 165 | 226 | 237 | 170 | 293 |
| Cash Conversion Cycle | -134 | -200 | -208 | 29 | -9 |
| Working Capital Days | 1 | -14 | -7 | 31 | 61 |
| ROCE % | 50% | 98% | 40% | 36% |
Guidance history
How Sat Kartar Life Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q2 FY27 call → | 20–40% | Up 2%+ | Planned | — | — |
| Q4 FY26 call → | 20–40% | Up 2%+ | Planned | — | Rising |
| Q2 FY26 call → | 40%+ | Up 2%+ | Planned | None planned | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Continue your research
What Sat Kartar Life Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY